Ocugen, Inc. (OCGN) Stock
OCGN Key Statistics
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
CEO: Shankar Musunuri. Company website
OCGN — Frequently Asked Questions
What is the OCGN stock price today?
Ocugen, Inc. (OCGN) trades at $0.79, down 3.08% on the day, as of Oct 23, 2026 00:45 UTC.
What is Ocugen, Inc.'s market cap?
Ocugen, Inc. has a market capitalisation of $267.90M, calculated from the live OCGN share price and shares outstanding.
What is the P/E ratio of OCGN?
OCGN has no meaningful price-to-earnings ratio: Ocugen, Inc. lost $0.25 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Ocugen, Inc. make?
Ocugen, Inc. generated revenue of $4.58M over the trailing twelve months, which puts the stock at 58.49 times sales.
What is the 52-week range for OCGN?
OCGN has traded between $0.78 and $2.73 over the past 52 weeks, and the last price is 71.1% below that high.
Is Ocugen, Inc. profitable?
No. Ocugen, Inc. is loss-making, with a net margin of -1,786.27% over the trailing twelve months.
What is the analyst price target for OCGN?
Wall Street analysts rate OCGN Buy, with an average price target of $5.00, 532.9% above the current price.
What sector is Ocugen, Inc. in?
Ocugen, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Ocugen, Inc.?
Shankar Musunuri is the chief executive of Ocugen, Inc., which employs 116 people.
Where can I track OCGN in real time?
QFI Terminal shows OCGN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See OCGN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open OCGN in Terminal See plans